Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM SR versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM SR versus TRIVARIS.
CARDIZEM SR vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
3.0-4.5 hours for diltiazem; metabolites (e.g., desacetyldiltiazem) up to 10 hours. Clinical context: dosing interval adjustment in hepatic impairment.
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Renal: 2-4% unchanged; hepatic metabolism: ~60-70% (including active metabolites); fecal: ~30-40%.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Calcium Channel Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination